文献速递淋巴瘤

Sovleplenib(HMPL-523)治疗复发/难治性淋巴瘤的1期开放标签多中心研究

Phase 1, open-label, multicenter study of sovleplenib (HMPL-523) in patients with relapsed or refractory lymphoma.
PubMed 文献 · Blood Adv · 2026-09-24

推荐2期剂量为700mg每日一次,最大耐受剂量未达到;常见≥3级不良事件为中性粒细胞减少、肝酶升高和血小板减少,无治疗相关死亡。在53例可评估患者中总体缓解率为30.2%,包括5例完全缓解,支持进一步研究。

要点

  • 推荐2期剂量为700mg每日一次,最大耐受剂量未达到。
  • 常见≥3级不良事件为中性粒细胞减少、肝酶升高和血小板减少,无治疗相关死亡。
  • 可评估患者总体缓解率30.2%,含5例完全缓解,中位缓解持续时间5.7–11.3个月。

核心结论

  • Sovleplenib在经多线治疗的复发/难治性淋巴瘤患者中安全性可控、药代动力学可预测,并显示初步抗肿瘤活性,支持进一步开展联合及更早线研究。

研究设计与样本

  • 剂量递增阶段为100–800mg每日一次,扩展阶段为700mg每日一次,覆盖多种淋巴瘤亚型。
  • 安全性按NCI CTCAE v5.0评估,疗效按Lugano 2014及疾病特异性标准评估。

主要发现

  • 推荐2期剂量为700mg每日一次,最大耐受剂量未达到。
  • 常见≥3级治疗中出现的不良事件包括中性粒细胞减少、肝酶升高和血小板减少,无治疗相关死亡。
  • 在推荐2期剂量或以上治疗的53例可评估患者中,总体缓解率为30.2%,包括5例完全缓解。
  • 关键队列缓解率:霍奇金淋巴瘤25.9%(n=27),BTK抑制剂后慢性淋巴细胞白血病28.6%(n=7),外周T细胞淋巴瘤33.3%(n=9)。
  • 中位缓解持续时间为5.7至11.3个月;药代动力学分析显示剂量比例暴露,每日给药约2倍蓄积。

关键数值与推荐

  • 推荐2期剂量:700mg每日一次。
  • 可评估患者总体缓解率30.2%,含5例完全缓解。
  • 霍奇金淋巴瘤缓解率25.9%(n=27),BTK抑制剂后CLL缓解率28.6%(n=7),外周T细胞淋巴瘤缓解率33.3%(n=9)。
  • 中位缓解持续时间范围5.7–11.3个月。

临床怎么用

  • Sovleplenib 700mg每日一次可作为复发/难治性淋巴瘤后续研究的推荐剂量。
  • 治疗期间需监测中性粒细胞减少、肝酶升高和血小板减少,并对症支持处理。
  • 现有数据支持在联合方案及更早线治疗中进一步评估sovleplenib。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Relapsed or refractory lymphoma carries poor prognosis, with limited options after standard therapies. Spleen tyrosine kinase (SYK) mediates B-cell receptor and aberrant T-cell receptor signaling, promoting survival and proliferation. HMPL-523 (sovleplenib) is a novel, selective oral SYK inhibitor with preclinical activity in lymphoid malignancies. This Phase 1, open-label, multicenter study (NCT03779113) enrolled adult patients with relapsed/refractory lymphoma who had exhausted approved therapies. The trial included dose escalation (100-800 mg once daily) and expansion (700 mg once daily) stages across multiple lymphoma subtypes. Safety was assessed per NCI CTCAE v5.0; efficacy per Lugano 2014 and disease-specific criteria. Sixty-nine patients were treated (Stage 1: n=21; Stage 2: n=48). The recommended Phase 2 dose was 700 mg once daily; the maximum tolerated dose was not reached. Common grade ≥3 treatment-emergent adverse events included neutropenia, elevated liver enzymes, and thrombocytopenia; no treatment-related deaths occurred. Among 53 response-evaluable patients across stage 1 and stage 2 who were treated at the recommended Phase 2 dose or above, overall response rate (ORR) was 30.2%, including 5 complete responses. ORR by key cohort was 25.9% for Hodgkin lymphoma (n=27), 28.6% for chronic lymphocytic leukemia post-Bruton's tyrosine kinase inhibitor (n=7), and 33.3% for peripheral T-cell lymphoma (n=9), with a median duration of response ranging from 5.7 to 11.3 months. Pharmacokinetic analysis showed dose-proportional exposure and ~2-fold accumulation with daily dosing. Sovleplenib demonstrated a safety profile managed with supportive medications, predictable pharmacokinetics, and preliminary antitumor activity in heavily pretreated lymphoma patients, supporting further investigation in combination and earlier-line settings. ClinicalTrials.gov Identifier: NCT03779113.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Strati P, Chraniuk D, González Barca E, et al. Phase 1, open-label, multicenter study of sovleplenib (HMPL-523) in patients with relapsed or refractory lymphoma. Blood Adv. 2026. PMID: 42782312. doi:10.1182/bloodadvances.2026021214

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。